STOCKHOLM, Sweden, Feb. 15, 2005 (PRIMEZONE) -- Vitrolife has been informed that the company’s patent application regarding the use of alanyl-glutamine in media for in vitro fertilization has been approved in the USA. “The advantage of alanyl-glutamine compared with glutamine, which was used previously, is that it is more stable and is not broken down into harmful substances that can inhibit the development of the embryo. The approval of this patent entails a competitive advantage for the company,” says Magnus Nilsson, Vitrolife’s CEO.
